로딩 중…
StockDiggingStockDigging

GSK plc

GSK· NYSE
GBGB
$50.23-1.64%
2026-09-18

Financials

Valuation Metrics

GSK plc's Market Cap is $100.79B. At end of 2025 it was $99.07B. Ranked #157 of 3,121 in US market (top 5%), #110 of 1,658 on NYSE (top 7%), #14 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 5%) by Market Cap.

Investment Metrics(as of 2026-09-18)

MetricValue
Size
Market Cap$100.79B
Revenue$43.78B
Net Income$6.36B
Total Assets$82.64B
Net Assets$23.62B
Employees66,841
Value
P/E15.86x
P/B4.27x
PEG0.39x
P/S2.30x
EV/EBITDA8.45x
FCF Yield9.13%
Profitability
ROE26.91%
ROA7.69%
Op. Margin20.70%
Revenue Growth4.97%
Earnings Growth40.84%
Financial Health
Debt Ratio252.54%
Total Debt$24.41B
FCF$9.20B
Cash$4.16B
Current Ratio0.82x
Net Debt/EBITDA1.41x
Dividend
Div. Yield3.80%
Div. Growth2.61%
Performance
1Y Return24.63%
1M Return-5.02%
From 52W High-18.60%
1Y MDD-21.35%
Trading
Volume4,059,344 shares
Trading Value$203M
Per Share
EPS$3.17
BPS$11.77

Company Info

CEO Luke Victor Miels
Employees 66,841
HQ London, GB

GSK plc, a global pharmaceutical entity founded in 1715 and headquartered in Brentford, United Kingdom, dedicates its efforts to the research, development, and manufacturing of a wide array of medical solutions. Until May 2022, the company was known as GlaxoSmithKline plc. Its primary objective is to prevent and treat illnesses by producing both vaccines and a comprehensive range of specialty and general medicines for markets across the United Kingdom, the United States, and internationally. The company's operations are organized into two key divisions: Commercial Operations and Total R&D. Its extensive vaccine portfolio includes immunizations against shingles, meningitis, respiratory syncytial virus (RSV), seasonal and pandemic influenza, and polio. Beyond preventative care, GSK provides diverse therapeutic products covering critical areas such as HIV, oncology, respiratory and immunology conditions, and other specialized medical fields. This also encompasses inhaled treatments for chronic respiratory ailments like asthma and chronic obstructive pulmonary disease (COPD), along with antibiotics for various infections. Innovation at GSK is frequently driven by strategic partnerships. Notable collaborations include an agreement with CureVac to advance mRNA-based influenza vaccines, and alliances with Wave Life Sciences and Elsie Biotechnologies focused on developing oligonucleotide platforms. Furthermore, GSK has established two distinct strategic collaborations with Relation to progress therapeutics for fibrotic diseases and osteoarthritis. The company is also engaged in a multi-target strategic alliance aimed at developing pioneering treatments for individuals suffering from Parkinson's disease, and a partnership with Flagship Pioneering to identify novel medicines and vaccines.